Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

BACKGROUND: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. METHODS: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. RESULTS: Three hundred twenty-two...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Jeffrey A, Bermel, Robert A, Grossman, Cynthia I, Hersh, Carrie M, Hyland, Megan, Mowry, Ellen M, Naismith, Robert, Naylor, Maria L, Nicholas, Jacqueline, Rajbhandar, Rajani, Singh, Carol M, Tintorè, Mar, Zabalza, Ana, Ziemssen, Tjalf, Williams, James R, Montalban, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131404/
https://www.ncbi.nlm.nih.gov/pubmed/34994577
http://dx.doi.org/10.1177/13524585211061343
_version_ 1784713167909158912
author Cohen, Jeffrey A
Bermel, Robert A
Grossman, Cynthia I
Hersh, Carrie M
Hyland, Megan
Mowry, Ellen M
Naismith, Robert
Naylor, Maria L
Nicholas, Jacqueline
Rajbhandar, Rajani
Singh, Carol M
Tintorè, Mar
Zabalza, Ana
Ziemssen, Tjalf
Williams, James R
Montalban, Xavier
author_facet Cohen, Jeffrey A
Bermel, Robert A
Grossman, Cynthia I
Hersh, Carrie M
Hyland, Megan
Mowry, Ellen M
Naismith, Robert
Naylor, Maria L
Nicholas, Jacqueline
Rajbhandar, Rajani
Singh, Carol M
Tintorè, Mar
Zabalza, Ana
Ziemssen, Tjalf
Williams, James R
Montalban, Xavier
author_sort Cohen, Jeffrey A
collection PubMed
description BACKGROUND: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. METHODS: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. RESULTS: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group. CONCLUSION: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.
format Online
Article
Text
id pubmed-9131404
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-91314042022-05-26 Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions Cohen, Jeffrey A Bermel, Robert A Grossman, Cynthia I Hersh, Carrie M Hyland, Megan Mowry, Ellen M Naismith, Robert Naylor, Maria L Nicholas, Jacqueline Rajbhandar, Rajani Singh, Carol M Tintorè, Mar Zabalza, Ana Ziemssen, Tjalf Williams, James R Montalban, Xavier Mult Scler Short Reports BACKGROUND: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. METHODS: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. RESULTS: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group. CONCLUSION: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs. SAGE Publications 2022-01-07 2022-06 /pmc/articles/PMC9131404/ /pubmed/34994577 http://dx.doi.org/10.1177/13524585211061343 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Short Reports
Cohen, Jeffrey A
Bermel, Robert A
Grossman, Cynthia I
Hersh, Carrie M
Hyland, Megan
Mowry, Ellen M
Naismith, Robert
Naylor, Maria L
Nicholas, Jacqueline
Rajbhandar, Rajani
Singh, Carol M
Tintorè, Mar
Zabalza, Ana
Ziemssen, Tjalf
Williams, James R
Montalban, Xavier
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
title Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
title_full Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
title_fullStr Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
title_full_unstemmed Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
title_short Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
title_sort immunoglobulin g immune response to sars-cov-2 vaccination in people living with multiple sclerosis within multiple sclerosis partners advancing technology and health solutions
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131404/
https://www.ncbi.nlm.nih.gov/pubmed/34994577
http://dx.doi.org/10.1177/13524585211061343
work_keys_str_mv AT cohenjeffreya immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT bermelroberta immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT grossmancynthiai immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT hershcarriem immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT hylandmegan immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT mowryellenm immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT naismithrobert immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT naylormarial immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT nicholasjacqueline immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT rajbhandarrajani immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT singhcarolm immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT tintoremar immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT zabalzaana immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT ziemssentjalf immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT williamsjamesr immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions
AT montalbanxavier immunoglobulingimmuneresponsetosarscov2vaccinationinpeoplelivingwithmultiplesclerosiswithinmultiplesclerosispartnersadvancingtechnologyandhealthsolutions

Ejemplares similares